TF and colonic neoplasm: This approach addresses: (a) what to deliver (engineered therapeutic CD44v6 shRNA), (b) how to deliver (delivery strategies using non-viral transferrin (Tf)-coated PEG-polyetheleneimine (PEI) (Tf-PEG-PEI) nanoparticles for in situ cell-specific therapy), and (c) where to deliver (tumor cell targets, in particular, colon tumor cells for in situ cell-specific therapy).